文献速递糖尿病

新型血管黏附蛋白-1抑制剂ASP8232降低糖尿病肾病患者白蛋白尿的疗效:ALBUM随机安慰剂对照2期试验

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2018-11-06

ALBUM试验在9个欧洲国家64个中心纳入125例2型糖尿病合并慢性肾脏病患者,随机接受ASP8232 40mg或安慰剂每日一次口服12周。

要点

  • ASP8232组治疗中出现不良事件61%,安慰剂组56%,药物相关不良事件分别为16例和4例。
  • ASP8232组最常见可能药物相关不良事件为肾功能损害5例和eGFR下降3例。

核心结论

  • ASP8232可有效降低糖尿病肾病患者的白蛋白尿,且安全性和耐受性良好。
  • 研究结果支持进一步研究ASP8232对延缓糖尿病肾病进展的作用。

研究设计与样本

  • 随机、双盲、安慰剂对照2期试验,在9个欧洲国家64个临床中心开展。
  • 纳入18-85岁2型糖尿病合并慢性肾脏病患者,随机分配接受ASP8232 40mg或安慰剂口服每日一次,治疗12周。
  • 主要终点为基线至第12周对数转换晨尿尿白蛋白肌酐比(UACR)的平均变化,在至少接受一剂研究药物且至少有一次基线后UACR测量的患者中评估(全分析集)。
  • 共125例参与者被随机分配至ASP8232组(n=64)或安慰剂组(n=61),其中120例(每组60例)纳入全分析集,所有参与者均评估安全性终点。

主要发现

  • ASP8232组39例(61%)和安慰剂组34例(56%)患者发生治疗中出现的不良事件,其中药物相关不良事件分别为16例和4例。
  • ASP8232组最常见可能药物相关不良事件为肾功能损害(5例)和eGFR下降(3例);安慰剂组无单一药物相关治疗中出现不良事件被超过一名参与者报告。

临床怎么用

  • 对于2型糖尿病合并慢性肾脏病且存在残余白蛋白尿的患者,ASP8232 40mg每日一次治疗12周可显著降低UACR。
  • 治疗期间需关注肾功能损害和eGFR下降等可能药物相关不良事件。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many patients with diabetic kidney disease have residual albuminuria and are at risk of disease progression. The ALBUM trial investigated the efficacy of a novel, orally active inhibitor of vascular adhesion protein-1, ASP8232, compared with placebo for reducing albuminuria in individuals with type 2 diabetes and chronic kidney disease. METHODS: In this randomised, double-blind, placebo-controlled phase 2 trial, we randomly assigned individuals (aged 18-85 years) from 64 clinical sites in nine European countries to receive ASP8232 40 mg or placebo orally once daily for 12 weeks using a web-based randomisation schedule (block size 4), stratified by country. Eligible patients had a urinary albumin-to-creatinine ratio (UACR) of 200-3000 mg/g, an estimated glomerular filtration rate of at least 25 mL/min per 1·73 m2 but lower than 75 mL/min per 1·73 m2, HbA1c less than 11·0% (97 mmol/mol), and stable treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and antidiabetic medication for 3 months or more. The primary endpoint was mean change from baseline to week 12 in log-transformed first morning void UACR, which was assessed in all patients who received at least one dose of study drug and had at least one post-baseline UACR measurement (full analysis set). Safety was assessed in all patients who received at least one dose of study drug. Participants and investigators were masked to treatment allocation. This trial is registered with ClinicalTrials.gov, number NCT02358096. FINDINGS: 125 participants were randomly assigned to receive ASP8232 (n=64) or placebo (n=61), of whom 120 (60 in each group) were included in the full analysis set; all participants were assessed for safety endpoints. At 12 weeks, UACR decreased by 17·7% (95% CI 5·0 to 28·6) in the ASP8232 group and increased by 2·3% (-11·4 to 18·1) in the placebo group; the placebo-adjusted difference between groups was -19·5% (95% CI -34·0 to -1·8; p=0·033). 39 (61%) patients in the ASP8232 group and 34 (56%) patients in the placebo group had a treatment-emergent adverse event, of which 16 in the ASP8232 group and four in the placebo group were drug-related. The most frequently reported adverse events that were possibly drug-related in the ASP8232 group were renal impairment (five patients) and decreased eGFR (three patients); in the placebo group, no single drug-related treatment-emergent adverse event was reported by more than one participant. INTERPRETATION: ASP8232 is effective in reducing albuminuria in patients with diabetic kidney disease and is safe and well tolerated. These findings warrant further research to ascertain the effect of ASP8232 on delaying progression of diabetic kidney disease. FUNDING: Astellas.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. de Zeeuw D, Renfurm RW, Bakris G, et al. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2018. PMID: 30413396. doi:10.1016/S2213-8587(18)30289-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。